New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up...
Hence then, the article about oncoinvent reports positive final data from phase 1 trial of radspherin to treat ovarian cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer )
Also on site :
- 2007 Career-Defining Hit, Inspired by a Reba McEntire Song, Is Still a Powerful Masterpiece 19 Years Later
- Iran destroys US spy Saildrone in Hormuz (VIDEO)
- Saratoga® Spring Water Steps Beyond the Bottle and onto the Runway with Public School New York Collaboration